Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis

Measuring symptom relief in studies of vaginal and vulvar atrophy

“…This has not been the case in previous studies. 14,15 Second, inclusion should be limited to women with one and preferably two moderate to severe VVA symptoms; otherwise, treatment effects will be too small to document. 8Y10 Third, changes in both individual symptoms and a composite score of all symptoms allow clinicians to better evaluate the effects of treatment.…”

COMPARISON OF EFFECT OF RED CLOVER & CONJUGATED ESTROGEN ON MENOPAUSAL SYMPTOMS AND THEIR IMPACT ON QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN

“…In conjugated estrogen group mean reduction in vaginal pH was from 6.80 (baseline) to 5.24 (12 week), hence the reduction was 1.56. [ 17] In another study, a meta-analysis reviewing randomized, placebo-controlled trials published between 1969 and 1995 determined that estrogen therapy, as compared to placebo, was efficacious in the treatment of post-menopausal women with signs and symptoms of vaginal atrophy. [18] In the Women"s HOPE trial, which included a dose of 0.3 mg conjugated equine estrogens with and without medroxyprogesterone acetate at 1.5 mg /day, significant changes from baseline Vaginal Maturation Index were reported after 6 and 13 cycles respectively.…”

Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women

“…Other low-dose oral estrogen therapies are indicated for the treatment of vulvovaginal atrophy (9, 10); however, the clinical trials evaluating these products for this indication used only the objective measurements of vaginal pH and VMI as primary efficacy endpoints (4,11), without simultaneously gauging the impact on patient symptoms (subjective symptomatology).…”